Decreased transfusion requirements in acquired severe bleeding with recombinant activated factor VII;Reducción de las necesidades transfusionales en hemorragias adquiridas graves mediante factor VII activo recombinante

Medicina Clinica

Volumn 125, Issue 7, 2005, Pages 252-253

  Lecumberri, Ramón ^a   Páramo, José A ^a   Hidalgo, Francisco ^a   Feliu, Jesús ^a   Iglesias, Rebeca ^a   Rocha, Eduardo ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Blood transfusion; Hemorrhage; Recombinant FVIIa

Indexed keywords

FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOTTING TEST; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; ERYTHROCYTE TRANSFUSION; EVALUATION; FEMALE; HEMOSTASIS; HUMAN; MALE; PLASMA TRANSFUSION; PROTHROMBIN TIME; RETROSPECTIVE STUDY; THROMBOCYTE TRANSFUSION; TREATMENT FAILURE;

EID: 25144432335     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13078100     Document Type: Article

References (10)

1. Sawyer PR, Harrison CR. Massive transfusion in adults. Diagnoses, survival and blood bank support. VoxSang. 1990;58:199-203.
2. Hedner U. Novoseven as a universal haemostatic agent. Blood Coagul Fibrinolysis. 2000;11 Suppl 1:107-11.
3. Goodnough LT. Utilization of recombinant factor VIIa (rFVIIa) in non-approved settings. Hematology (ASH Education program Book). 2004;1:466-70.
4. Bosch J, Thabut D, Bendtsen F, D'Amico G, Albillos A, González Abraldes J, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized double-blind trial. Gastroenterology. 2004;127:1123-30.
5. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352:777-85.
6. Martinowitz U, Kenet G, Segal E, Luboshitz L, Lubetsky A, Ingerslev J, et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma. 2001;51:431-8.
7. Eikelboom JW, Bird R, Blythe D, Coyle L, Gan E, Harvey M, et al. Recombinant activated factor VII for the treatment of life-threatening haemorrhage. Blood Coagul Fibrinolysis. 2003;14:713-7.
8. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med. 1999;340:409-17.
9. Páramo JA, Lecumberri R, Hernández M, Rocha E. Alternativas farmacológicas a la transfusión sanguínea. ¿Qué hay de nuevo? Med Clin (Barc). 2004;122:231-6.
10. Lollike K. Current Novo Nordisk sponsored clinical trials on NovoSeven® outside haemophilia. Haematologica. 2004;89 Suppl 5:16-7.